{"title":"PDE5Is在男性糖尿病和心血管疾病中的作用越来越大","authors":"G. Hackett, M. Kirby","doi":"10.1002/tre.926","DOIUrl":null,"url":null,"abstract":"Diabetes is strongly associated with erectile dysfunction, which is itself a risk factor for cardiovascular events and mortality. Evidence shows that phosphodiesterase type 5 inhibitor (PDE5I) use in men with type 2 diabetes mellitus is associated with a significant reduction in all‐cause mortality and morbidity. Despite the evidence, PDE5Is appear to be underused in this male cohort.","PeriodicalId":42819,"journal":{"name":"Trends in Urology & Mens Health","volume":"13 1","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The increasing role of PDE5Is in men with diabetes and cardiovascular disease\",\"authors\":\"G. Hackett, M. Kirby\",\"doi\":\"10.1002/tre.926\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Diabetes is strongly associated with erectile dysfunction, which is itself a risk factor for cardiovascular events and mortality. Evidence shows that phosphodiesterase type 5 inhibitor (PDE5I) use in men with type 2 diabetes mellitus is associated with a significant reduction in all‐cause mortality and morbidity. Despite the evidence, PDE5Is appear to be underused in this male cohort.\",\"PeriodicalId\":42819,\"journal\":{\"name\":\"Trends in Urology & Mens Health\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in Urology & Mens Health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/tre.926\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Urology & Mens Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/tre.926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
The increasing role of PDE5Is in men with diabetes and cardiovascular disease
Diabetes is strongly associated with erectile dysfunction, which is itself a risk factor for cardiovascular events and mortality. Evidence shows that phosphodiesterase type 5 inhibitor (PDE5I) use in men with type 2 diabetes mellitus is associated with a significant reduction in all‐cause mortality and morbidity. Despite the evidence, PDE5Is appear to be underused in this male cohort.